Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Immunol Res ; 2021: 9998200, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34104654

RESUMEN

The microbiome exerts considerable control over immune homeostasis and influences susceptibility to autoimmune and autoinflammatory disease (AD/AID) such as inflammatory bowel disease (IBD), multiple sclerosis (MS), type 1 diabetes (T1D), psoriasis, and uveitis. In part, this is due to direct effects of the microbiome on gastrointestinal (GI) physiology and nutrient transport, but also to indirect effects on immunoregulatory controls, including induction and stabilization of T regulatory cells (T reg). Secreted bacterial metabolites such as short-chain fatty acids (SCFA) are under intense investigation as mediators of these effects. In contrast, folate (vitamin B9), an essential micronutrient, has attracted less attention, possibly because it exerts global physiological effects which are difficult to differentiate from specific effects on the immune system. Here, we review the role of folate in AD/AID with some emphasis on sight-threatening autoimmune uveitis. Since folate is required for the generation and maintenance of T reg , we propose that one mechanism for microbiome-based control of AD/AID is via folate-dependent induction of GI tract T reg , particularly colonic T reg, via anergic T cells (T an). Hence, folate supplementation has potential prophylactic and/or therapeutic benefit in AID/AD.


Asunto(s)
Enfermedades Autoinmunes/inmunología , Autoinmunidad , Ácido Fólico/metabolismo , Microbioma Gastrointestinal/inmunología , Inflamación/inmunología , Animales , Enfermedades Autoinmunes/dietoterapia , Enfermedades Autoinmunes/metabolismo , Enfermedades Autoinmunes/microbiología , Modelos Animales de Enfermedad , Ácido Fólico/administración & dosificación , Humanos , Inflamación/dietoterapia , Inflamación/metabolismo , Inflamación/microbiología , Mucosa Intestinal/inmunología , Mucosa Intestinal/metabolismo , Mucosa Intestinal/microbiología , Linfocitos T Reguladores/inmunología , Linfocitos T Reguladores/metabolismo
2.
Am J Chin Med ; 49(2): 237-268, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33622213

RESUMEN

Intestinal flora is essential for maintaining host health and plays a unique role in transforming Traditional Chinese Medicine (TCM). TCM, as a bodyguard, has saved countless lives and maintained human health in the long history, especially in this COVID-19 pandemic. Pains of diseases have been removed from the effective TCM therapy, such as TCM preparation, moxibustion, and acupuncture. With the development of life science and technology, the wisdom and foresight of TCM has been more displayed. Furthermore, TCM has been also inherited and developed in innovation to better realize the modernization and globalization. Nowadays, intestinal flora transforming TCM and TCM targeted intestinal flora treating diseases have been important findings in life science. More and more TCM researches showed the significance of intestinal flora. Intestinal flora is also a way to study TCM to elucidate the profound theory of TCM. Processing, compatibility, and properties of TCM are well demonstrated by intestinal flora. Thus, it is no doubt that intestinal flora is a core in TCM study. The interaction between intestinal flora and TCM is so crucial for host health. Therefore, it is necessary to sum up the latest results in time. This paper systematically depicted the profile of TCM and the importance of intestinal flora in host. What is more, we comprehensively summarized and discussed the latest progress of the interplay between TCM and intestinal flora to better reveal the core connotation of TCM.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Disbiosis/microbiología , Microbioma Gastrointestinal , Medicina Tradicional China , Enfermedades Autoinmunes/microbiología , Enfermedades Autoinmunes/terapia , COVID-19 , Enfermedades Cardiovasculares/microbiología , Enfermedades Cardiovasculares/terapia , Diabetes Mellitus/microbiología , Diabetes Mellitus/terapia , Electroacupuntura , Enfermedades Gastrointestinales/microbiología , Enfermedades Gastrointestinales/terapia , Humanos , Enfermedades Metabólicas/microbiología , Enfermedades Metabólicas/terapia , Neoplasias/microbiología , Neoplasias/terapia , Enfermedad del Hígado Graso no Alcohólico/microbiología , Enfermedad del Hígado Graso no Alcohólico/terapia , Obesidad/microbiología , Obesidad/terapia , Insuficiencia Renal Crónica/microbiología , Insuficiencia Renal Crónica/terapia , SARS-CoV-2
3.
Immunol Lett ; 228: 45-54, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-33035575

RESUMEN

With a rise in the incidence of autoimmune diseases (AiD), health care providers continue to seek out more efficacious treatment approaches for the AiD patient population. Classic serotonergic psychedelics have recently been gaining public and professional interest as novel interventions to a number of mental health afflictions. Psychedelics have also been shown to be able to modulate immune functions, however, while there has been great interest to researching into their psychotherapeutic applications, there has so far been very little exploration into the potential to treat inflammatory and immune-related diseases with these compounds. A handful of studies from a variety of fields suggest that psychedelics do indeed have effects in the body that may attenuate the outcome of AiD. This literature review explores existing evidence that psychedelic compounds may offer a potential novel application in the treatment of pathologies related to autoimmunity. We propose that psychedelics hold the potential to attenuate or even resolve autoimmunity by targeting psychosomatic origins, maladaptive chronic stress responses, inflammatory pathways, immune modulation and enteric microbiome populations.


Asunto(s)
Enfermedades Autoinmunes/tratamiento farmacológico , Autoinmunidad/efectos de los fármacos , Bacterias/efectos de los fármacos , Microbioma Gastrointestinal/efectos de los fármacos , Alucinógenos/uso terapéutico , Factores Inmunológicos/uso terapéutico , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/microbiología , Enfermedades Autoinmunes/psicología , Bacterias/inmunología , Disbiosis , Microbioma Gastrointestinal/inmunología , Alucinógenos/efectos adversos , Humanos , Factores Inmunológicos/efectos adversos
4.
PLoS Negl Trop Dis ; 13(9): e0007368, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31504035

RESUMEN

Up to 50% of patients with the multibacillary form of leprosy are expected to develop acute systemic inflammatory episodes known as type 2 reactions (T2R), thus aggravating their clinical status. Thalidomide rapidly improves T2R symptoms. But, due to its restricted use worldwide, novel alternative therapies are urgently needed. The T2R triggering mechanisms and immune-inflammatory pathways involved in its pathology remain ill defined. In a recent report, we defined the recognition of nucleic acids by TLR9 as a major innate immunity pathway that is activated during T2R. DNA recognition has been described as a major inflammatory pathway in several autoimmune diseases, and neutrophil DNA extracellular traps (NETs) have been shown to be a prime source of endogenous DNA. Considering that neutrophil abundance is a marked characteristic of T2R lesions, the objective of this study was to investigate NETs production in T2R patients based on the hypothesis that the excessive NETs formation would play a major role in T2R pathogenesis. Abundant NETs were found in T2R skin lesions, and increased spontaneous NETs formation was observed in T2R peripheral neutrophils. Both the M. leprae whole-cell sonicate and the CpG-Hlp complex, mimicking a mycobacterial TLR9 ligand, were able to induce NETs production in vitro. Moreover, TLR9 expression was shown to be higher in T2R neutrophils, suggesting that DNA recognition via TLR9 may be one of the pathways triggering this process during T2R. Finally, treatment of T2R patients with thalidomide for 7 consecutive days resulted in a decrease in all of the evaluated in vivo and ex vivo NETosis parameters. Altogether, our findings shed light on the pathogenesis of T2R, which, it is hoped, will contribute to the emergence of novel alternative therapies and the identification of prognostic reactional markers in the near future.


Asunto(s)
Trampas Extracelulares/inmunología , Inmunidad Innata , Lepra/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/microbiología , Femenino , Humanos , Inflamación/inmunología , Inflamación/patología , Lepra/tratamiento farmacológico , Lepra/patología , Masculino , Persona de Mediana Edad , Mycobacterium leprae/inmunología , Mycobacterium leprae/patogenicidad , Neutrófilos/patología , Talidomida/administración & dosificación , Talidomida/uso terapéutico
5.
Autoimmun Rev ; 18(5): 455-475, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30844549

RESUMEN

The role of microorganism in human diseases cannot be ignored. These microorganisms have evolved together with humans and worked together with body's mechanism to maintain immune and metabolic function. Emerging evidence shows that gut microbe and their metabolites open up new doors for the study of human response mechanism. The complexity and interdependence of these microbe-metabolite-host interactions are rapidly being elucidated. There are various changes of microbial levels in models or in patients of various autoimmune diseases (AIDs). In addition, the relevant metabolites involved in mechanism mainly include short-chain fatty acids (SCFAs), bile acids (BAs), and polysaccharide A (PSA). Meanwhile, the interaction between microbes and host genes is also a factor that must be considered. It has been demonstrated that human microbes are involved in the development of a variety of AIDs, including organ-specific AIDs and systemic AIDs. At the same time, microbes or related products can be used to remodel body's response to alleviate or cure diseases. This review summarizes the latest research of microbes and their related metabolites in AIDs. More importantly, it highlights novel and potential therapeutics, including fecal microbial transplantation, probiotics, prebiotics, and synbiotics. Nonetheless, exact mechanisms still remain elusive, and future research will focus on finding a specific strain that can act as a biomarker of an autoimmune disease.


Asunto(s)
Enfermedades Autoinmunes/metabolismo , Enfermedades Autoinmunes/microbiología , Enfermedades Autoinmunes/terapia , Interacciones Microbiota-Huesped/fisiología , Enfermedades Autoinmunes/inmunología , Autoinmunidad/fisiología , Trasplante de Microbiota Fecal/métodos , Microbioma Gastrointestinal/inmunología , Microbioma Gastrointestinal/fisiología , Humanos , Redes y Vías Metabólicas/inmunología , Prebióticos/microbiología , Probióticos/metabolismo , Probióticos/uso terapéutico
6.
Invest Ophthalmol Vis Sci ; 60(1): 420-429, 2019 01 02.
Artículo en Inglés | MEDLINE | ID: mdl-30695094

RESUMEN

Purpose: We determine the changes in intestinal microbiota and/or disruptions in intestinal homeostasis during uveitis. Methods: Experimental autoimmune uveitis (EAU) was induced in B10.RIII mice with coadministration of interphotoreceptor retinoid-binding protein peptide (IRBP) and killed mycobacterial antigen (MTB) as an adjuvant. Using 16S rRNA gene sequencing, we looked at intestinal microbial differences during the course of uveitis, as well as intestinal morphologic changes, changes in intestinal permeability by FITC-dextran leakage, antimicrobial peptide expression in the gastrointstinal tract, and T lymphocyte prevalence before and at peak intraocular inflammation. Results: We demonstrate that increased intestinal permeability and antimicrobial peptide expression in the intestinal tract coincide in timing with increased effector T cells in the mesenteric lymph nodes, during the early stages of uveitis, before peak inflammation. Morphologic changes in the intestine were most prominent during this phase, but also occurred with adjuvant MTB alone, whereas increased intestinal permeability was found only in IRBP-immunized mice that develop uveitis. We also demonstrate that the intestinal microbiota were altered during the course of uveitis, and that some of these changes are specific to uveitic animals, whereas others are influenced by adjuvant MTB alone. Intestinal permeability peaked at 2 weeks, coincident with an increase in intestinal bacterial strain differences, peak lipocalin production, and peak uveitis. Conclusions: An intestinal dysbiosis accompanies a disruption in intestinal homeostasis in autoimmune uveitis, although adjuvant MTB alone promotes intestinal disruption as well. This may indicate a novel axis for future therapeutic targeting experimentally or clinically.


Asunto(s)
Enfermedades Autoinmunes/microbiología , Disbiosis/microbiología , Microbioma Gastrointestinal/inmunología , Homeostasis/fisiología , Intestinos/fisiología , Uveítis/microbiología , Animales , Antígenos Bacterianos/inmunología , Enfermedades Autoinmunes/inmunología , Ensayo de Inmunoadsorción Enzimática , Proteínas del Ojo , Citometría de Flujo , Lipocalinas/metabolismo , Ratones , Ratones Mutantes , Modelos Animales , Mycobacterium tuberculosis/genética , Mycobacterium tuberculosis/inmunología , ARN Ribosómico 16S/genética , Proteínas de Unión al Retinol , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Subgrupos de Linfocitos T/inmunología , Uveítis/inmunología , Proteína de la Zonula Occludens-1/metabolismo
7.
Inflammopharmacology ; 27(2): 373-385, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30446926

RESUMEN

Ankylosing spondylitis, multiple sclerosis, rheumatoid arthritis and rheumatic fever are autoimmune inflammatory diseases that may be triggered in genetically susceptible individuals by specific bacterial pathogens. Inhibiting the growth of these bacteria with high antioxidant plant extracts may inhibit the aetiology of these diseases, as well as inhibiting the later phase symptoms. P. squarrosa extracts were analysed for antioxidant activity using a DPPH free radical scavenging assay. Bacterial growth inhibitory activity was evaluated using disc diffusion assays and the activity was quantified by MIC determination. The extracts were screened for toxicity by A. franciscana nauplii assays. The most potent antibacterial extract (ethyl acetate) was analysed by GC-MS headspace profile analysis and compounds were identified with reference to a phytochemical database. All extracts displayed strong DPPH radical scavenging activity. The ethyl acetate extract was particularly potent (IC50 1.4 µg/mL), whilst the other extracts also had significant radical scavenging activity (IC50 values between 11 and 22 µg/mL). Notably, the bacterial growth inhibitory activity of the extracts correlated with their DPPH radical scavenging activity. The ethyl acetate extract, which had the greatest DPPH scavenging activity, generally displayed the most potent bacterial growth inhibitory activity. This extract was particularly potent against P. mirabilis, P. vulgaris and A. baylyi (MIC values of 484, 575 and 880 µg/mL, respectively). It also inhibited P. aeruginosa and S. pyogenes growth, albeit with higher MICs (1600-3700 µg/mL). All other extract-bacteria combinations were either inactive or resulted in mid-low potency inhibition. All extracts were non-toxic in the A. franciscana bioassay (LC50 substantially > 1000 µg/mL). In total, 89 unique mass signals were identified in the P. squarrosa ethyl acetate extract by non-biased GC-MS headspace analysis. A number of compounds which may contribute to the antibacterial activity of this extract have been highlighted.


Asunto(s)
Antibacterianos/farmacología , Enfermedades Autoinmunes/microbiología , Bacterias/efectos de los fármacos , Extractos Vegetales/farmacología , Plantago/química , Antioxidantes/farmacología , Cromatografía de Gases y Espectrometría de Masas/métodos , Pruebas de Sensibilidad Microbiana/métodos , Hojas de la Planta/química
8.
Clin Infect Dis ; 68(9): 1463-1471, 2019 04 24.
Artículo en Inglés | MEDLINE | ID: mdl-30307492

RESUMEN

BACKGROUND: Triazole resistance is an increasing problem in invasive aspergillosis (IA). Small case series show mortality rates of 50%-100% in patients infected with a triazole-resistant Aspergillus fumigatus, but a direct comparison with triazole-susceptible IA is lacking. METHODS: A 5-year retrospective cohort study (2011-2015) was conducted to compare mortality in patients with voriconazole-susceptible and voriconazole-resistant IA. Aspergillus fumigatus culture-positive patients were investigated to identify patients with proven, probable, and putative IA. Clinical characteristics, day 42 and day 90 mortality, triazole-resistance profiles, and antifungal treatments were investigated. RESULTS: Of 196 patients with IA, 37 (19%) harbored a voriconazole-resistant infection. Hematological malignancy was the underlying disease in 103 (53%) patients, and 154 (79%) patients were started on voriconazole. Compared with voriconazole-susceptible cases, voriconazole resistance was associated with an increase in overall mortality of 21% on day 42 (49% vs 28%; P = .017) and 25% on day 90 (62% vs 37%; P = .0038). In non-intensive care unit patients, a 19% lower survival rate was observed in voriconazole-resistant cases at day 42 (P = .045). The mortality in patients who received appropriate initial voriconazole therapy was 24% compared with 47% in those who received inappropriate therapy (P = .016), despite switching to appropriate antifungal therapy after a median of 10 days. CONCLUSIONS: Voriconazole resistance was associated with an excess overall mortality of 21% at day 42 and 25% at day 90 in patients with IA. A delay in the initiation of appropriate antifungal therapy was associated with increased overall mortality.


Asunto(s)
Aspergillus fumigatus/genética , Enfermedades Autoinmunes/tratamiento farmacológico , Farmacorresistencia Fúngica/genética , Neoplasias Hematológicas/tratamiento farmacológico , Aspergilosis Pulmonar Invasiva/tratamiento farmacológico , Voriconazol/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antifúngicos/uso terapéutico , Aspergillus fumigatus/efectos de los fármacos , Aspergillus fumigatus/patogenicidad , Enfermedades Autoinmunes/complicaciones , Enfermedades Autoinmunes/microbiología , Enfermedades Autoinmunes/mortalidad , Niño , Preescolar , Femenino , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/microbiología , Neoplasias Hematológicas/mortalidad , Humanos , Aspergilosis Pulmonar Invasiva/complicaciones , Aspergilosis Pulmonar Invasiva/microbiología , Aspergilosis Pulmonar Invasiva/mortalidad , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Retrospectivos , Análisis de Supervivencia , Factores de Tiempo
9.
Microbiome ; 5(1): 63, 2017 06 23.
Artículo en Inglés | MEDLINE | ID: mdl-28645307

RESUMEN

BACKGROUND: Perturbation of commensal intestinal microbiota has been associated with several autoimmune diseases. Mice deficient in interleukin-1 receptor antagonist (Il1rn -/- mice) spontaneously develop autoimmune arthritis and are susceptible to other autoimmune diseases such as psoriasis, diabetes, and encephalomyelitis; however, the mechanisms of increased susceptibility to these autoimmune phenotypes are poorly understood. We investigated the role of interleukin-1 receptor antagonist (IL-1Ra) in regulation of commensal intestinal microbiota, and assessed the involvement of microbiota subsets and innate and adaptive mucosal immune responses that underlie the development of spontaneous arthritis in Il1rn -/- mice. RESULTS: Using high-throughput 16S rRNA gene sequencing, we show that IL-1Ra critically maintains the diversity and regulates the composition of intestinal microbiota in mice. IL-1Ra deficiency reduced the intestinal microbial diversity and richness, and caused specific taxonomic alterations characterized by overrepresented Helicobacter and underrepresented Ruminococcus and Prevotella. Notably, the aberrant intestinal microbiota in IL1rn -/- mice specifically potentiated IL-17 production by intestinal lamina propria (LP) lymphocytes and skewed the LP T cell balance in favor of T helper 17 (Th17) cells, an effect transferable to WT mice by fecal microbiota. Importantly, LP Th17 cell expansion and the development of spontaneous autoimmune arthritis in IL1rn -/- mice were attenuated under germ-free condition. Selective antibiotic treatment revealed that tobramycin-induced alterations of commensal intestinal microbiota, i.e., reduced Helicobacter, Flexispira, Clostridium, and Dehalobacterium, suppressed arthritis in IL1rn -/- mice. The arthritis phenotype in IL1rn -/- mice was previously shown to depend on Toll-like receptor 4 (TLR4). Using the ablation of both IL-1Ra and TLR4, we here show that the aberrations in the IL1rn -/- microbiota are partly TLR4-dependent. We further identify a role for TLR4 activation in the intestinal lamina propria production of IL-17 and cytokines involved in Th17 differentiation preceding the onset of arthritis. CONCLUSIONS: These findings identify a critical role for IL1Ra in maintaining the natural diversity and composition of intestinal microbiota, and suggest a role for TLR4 in mucosal Th17 cell induction associated with the development of autoimmune disease in mice.


Asunto(s)
Artritis/inmunología , Microbioma Gastrointestinal , Enfermedades Autoinflamatorias Hereditarias/inmunología , Proteína Antagonista del Receptor de Interleucina 1/fisiología , Interleucina-17/inmunología , Receptor Toll-Like 4/inmunología , Animales , Antibacterianos/administración & dosificación , Artritis/microbiología , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/microbiología , Variación Genética , Helicobacter/genética , Enfermedades Autoinflamatorias Hereditarias/microbiología , Secuenciación de Nucleótidos de Alto Rendimiento , Proteína Antagonista del Receptor de Interleucina 1/deficiencia , Proteína Antagonista del Receptor de Interleucina 1/genética , Proteína Antagonista del Receptor de Interleucina 1/inmunología , Mucosa Intestinal/inmunología , Mucosa Intestinal/microbiología , Ratones , Ratones Noqueados , Membrana Mucosa/inmunología , Membrana Mucosa/microbiología , Prevotella/genética , ARN Ribosómico 16S , Ruminococcus/genética , Células Th17/inmunología , Receptor Toll-Like 4/genética
10.
Clin Rheumatol ; 33(7): 893-901, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24894108

RESUMEN

Acute rheumatic fever (ARF) is a non-suppurative complication of pharyngeal infection with group A streptococcus. Signs and symptoms of ARF develop 2 to 3 weeks following pharyngitis and include arthritis, carditis, chorea, subcutaneous nodules, and erythema marginatum. In developing areas of the world, ARF and rheumatic heart disease are estimated to affect nearly 20 million people and remain leading causes of cardiovascular death during the first five decades of life. ARF still represents one of the quintessential examples of a pathogenic trigger culminating in autoimmune manifestations. In this review, we will focus on the pathogenesis and etiology of ARF and its complications, along with diagnostic and treatment approaches to both ameliorate and prevent long-term sequelae of this potentially debilitating disease.


Asunto(s)
Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/microbiología , Fiebre Reumática/inmunología , Fiebre Reumática/microbiología , Infecciones Estreptocócicas/inmunología , Infecciones Estreptocócicas/microbiología , Streptococcus pyogenes/patogenicidad , Antibacterianos/uso terapéutico , Artritis/complicaciones , Artritis/microbiología , Autoinmunidad/inmunología , Corea/complicaciones , Corea/microbiología , Eritema/complicaciones , Eritema/microbiología , Humanos , Inflamación , Microbiota , Miocarditis/complicaciones , Miocarditis/microbiología , Faringitis/complicaciones , Faringitis/microbiología , Enfermedades Reumáticas , Cardiopatía Reumática/complicaciones , Cardiopatía Reumática/microbiología
12.
BMC Oral Health ; 14: 14, 2014 Feb 20.
Artículo en Inglés | MEDLINE | ID: mdl-24552136

RESUMEN

BACKGROUND: The isolation frequency and susceptibility to antifungal agents of oral Candida isolates from patients with oral candidiasis (OC) were compared between studies conducted in 2006-2007 and 2012-2013. METHODS: A total158 strains was isolated from 112 patients who visited Kagoshima University Hospital for the treatment of OC during the 14-month period from February 2012 and March 2013, and evaluated on the isolation frequency of each Candida strain and the susceptibility against antifungal drugs as compared to those evaluated in 2006-2007. RESULTS: There was a higher frequency of xerostomia as a chief complaint and of autoimmune disease in the 2012-2013 study than in the 2006-2007 study. More than 95% of Candida isolates were C. albicans and C. glabrata. In addition, the proportion of the latter increased from 12.3% in the 2006-2007 study to 23.4% in the 2012-2013 study, while the proportion of the former decreased from 86.2% to 72.8%, respectively. C. albicans was isolated in almost all patients, while C. glabrata was only isolated concomitantly with C. albicans. Minimal inhibitory concentrations (MICs) were not significantly different between groups with a few exceptions. Candida isolates, of which MICs surpassed break points, apparently increased for miconazole and itraconazole against C. glabrata in the 2012-2013 study, but this was not statistically significant. As a result, more cases of autoimmune disease, a greater number of C. glabrata isolates, and higher resistance to azoles were seen in the 2012-2013 study than in the 2006-2007 study. CONCLUSION: These data indicate that with recent increases in C. glabrata infection, a causative fungus of OC, and in C. glabrata resistance to azoles, caution is needed in the selection of antifungal drugs for the treatment of OC.


Asunto(s)
Antifúngicos/uso terapéutico , Candida/aislamiento & purificación , Candidiasis Bucal/microbiología , Farmacorresistencia Fúngica , Adulto , Anciano , Anciano de 80 o más Años , Anfotericina B/uso terapéutico , Enfermedades Autoinmunes/microbiología , Carga Bacteriana , Candida/clasificación , Candida/efectos de los fármacos , Candida albicans/efectos de los fármacos , Candida albicans/aislamiento & purificación , Candida glabrata/efectos de los fármacos , Candida glabrata/aislamiento & purificación , Candidiasis Bucal/tratamiento farmacológico , Coinfección/microbiología , Equinocandinas/uso terapéutico , Femenino , Fluconazol/uso terapéutico , Flucitosina/uso terapéutico , Humanos , Itraconazol/uso terapéutico , Japón , Lipopéptidos/uso terapéutico , Masculino , Micafungina , Miconazol/uso terapéutico , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Xerostomía/microbiología
13.
J Autoimmun ; 47: 58-72, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24075646

RESUMEN

Autoimmunity is associated with a strong genetic component, but onset and persistence of clinically apparent autoimmune diseases often require an additional environmental trigger. The balance between immunity and tolerance is regulated by numerous molecular factors including nuclear hormone and homeostatic chemokine receptors. The nuclear hormone receptor RORγt and the chemokine receptor CCR7 are both essentially involved in functional lymphoid organogenesis and maintenance of lymphocyte homeostasis. Lack of one or the other impairs thymic T cell development and alters T cell homeostasis. Mice deficient for both, Ccr7(-/-)Rorγt(-/-), succumbed early to acute destructive inflammation, characterized by massive recruitment of inflammatory leukocytes, pro-inflammatory cytokine and autoantibody production, and wasting disease. Antibiotic-treatment of mice before disease onset reduced the overall gut microflora and abrogated the development of fatal mucosal inflammation. Hence, commensal bacteria and a confined tissue-specific inflammatory milieu serve as complementary trigger to initiate the lethal pathophysiologic process in Ccr7(-/-)Rorγt(-/-) mice.


Asunto(s)
Enfermedades Autoinmunes/genética , Enfermedades Autoinmunes/inmunología , Autoinmunidad/inmunología , Mucosa Intestinal/microbiología , Microbiota , Miembro 3 del Grupo F de la Subfamilia 1 de Receptores Nucleares/genética , Receptores CCR7/genética , Ampicilina/uso terapéutico , Animales , Antibacterianos/uso terapéutico , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/microbiología , Linfocitos T CD4-Positivos/inmunología , Diferenciación Celular/inmunología , Quimera/inmunología , Colistina/uso terapéutico , Inflamación/inmunología , Mucosa Intestinal/inmunología , Leucocitos/inmunología , Activación de Linfocitos/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Estreptomicina/uso terapéutico
14.
Curr Opin Rheumatol ; 25(2): 234-40, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23370376

RESUMEN

PURPOSE OF REVIEW: To demonstrate how dysbiosis of the human microbiome can drive autoimmune disease. RECENT FINDINGS: Humans are superorganisms. The human body harbors an extensive microbiome, which has been shown to differ in patients with autoimmune diagnoses. Intracellular microbes slow innate immune defenses by dysregulating the vitamin D nuclear receptor, allowing pathogens to accumulate in tissue and blood. Molecular mimicry between pathogen and host causes further dysfunction by interfering with human protein interactions. Autoantibodies may well be created in response to pathogens. SUMMARY: The catastrophic failure of human metabolism observed in autoimmune disease results from a common underlying pathogenesis - the successive accumulation of pathogens into the microbiome over time, and the ability of such pathogens to dysregulate gene transcription, translation, and human metabolic processes. Autoimmune diseases are more likely passed in families because of the inheritance of a familial microbiome, rather than Mendelian inheritance of genetic abnormalities. We can stimulate innate immune defenses and allow patients to target pathogens, but cell death results in immunopathology.


Asunto(s)
Autoinmunidad , Metagenoma/inmunología , Adyuvantes Inmunológicos/uso terapéutico , Autoanticuerpos/biosíntesis , Enfermedades Autoinmunes/etiología , Enfermedades Autoinmunes/microbiología , Enfermedades Autoinmunes/terapia , Familia , Femenino , Interacciones Huésped-Patógeno/inmunología , Humanos , Inmunidad Innata , Infecciones/inmunología , Infecciones/microbiología , Masculino , Modelos Inmunológicos , Imitación Molecular/inmunología , Polimorfismo de Nucleótido Simple , Receptores de Calcitriol/inmunología
15.
Immunol Lett ; 36(2): 227-31, 1993 May.
Artículo en Inglés | MEDLINE | ID: mdl-8349317

RESUMEN

Pristane-induced arthritis (PIA) is unique among the animal arthritides in that a non-infectious, non-antigenic oil induces a chronic immune based arthritis with a prolonged delay between exposure to the inciting agent and development of the disease. Mice with pristane-induced arthritis have elevated T cell and humoral responses to the 65 kDa heat shock protein derived from Mycobacterium bovis (hsp65) and in common with several other models of autoimmune diseases the incidence of PIA is markedly suppressed by preimmunisation with hsp65 in Freund's incomplete adjuvant (Thompson et al. (1990) Eur. J. Immunol. 20, 2479). Recent studies have investigated how autoimmune reactions to heat shock proteins are involved in the development of arthritis. Arthritic CBA/Igb mice given pristane alone develop antibodies to both hsp65 and GroEl (bacterial 60 kDa heat shock proteins) and to hsp58 (the mammalian equivalent). Moreover, the splenic T cells of such mice proliferate vigorously in response to both bacterial and mammalian 60 kDa heat shock proteins. Remarkably, the anti-hsp65 antibody response in normal mice rises rapidly with age, directly correlating with the age related incidence of PIA. In addition, specific pathogen free mice (SPF) maintained in an isolator have negligible anti-hsp65 responses but these convert to positive responses if the animals are exposed to the open part of the animal facility (Thompson et al. (1992) Arthritis Rheum. 35, 139).(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Artritis/etiología , Enfermedades Autoinmunes/inmunología , Bacterias Aerobias/inmunología , Intestinos/microbiología , Peritonitis/inducido químicamente , Terpenos/toxicidad , Animales , Artritis/inmunología , Artritis/microbiología , Enfermedades Autoinmunes/inducido químicamente , Enfermedades Autoinmunes/microbiología , Bacterias Aerobias/aislamiento & purificación , Proteínas Bacterianas/inmunología , Susceptibilidad a Enfermedades/microbiología , Heces/microbiología , Vida Libre de Gérmenes , Proteínas de Choque Térmico/inmunología , Inyecciones Intraperitoneales , Masculino , Ratones , Ratones Endogámicos DBA/genética , Ratones Endogámicos DBA/inmunología , Ratones Endogámicos DBA/microbiología , Peritonitis/complicaciones , Organismos Libres de Patógenos Específicos , Linfocitos T Citotóxicos/inmunología , Terpenos/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA